中
About
Our Mission & Vision
Team
Leadership
Board of Directors
Scientific Advisory Board
Milestones
Pipeline
Ophthalmology
Neurology & Psychiatry
Partnership
Business Development
Our Partners
Newsroom
Press Releases
In The News
Media Room
Careers
Value & Behaviors
Benefits
Open Positions
Contact
About
Our Mission & Vision
Team
Milestones
Pipeline
Ophthalmology
Neurology & Psychiatry
Partnership
Business Development
Our Partners
Newsroom
Press Releases
In The News
Media Room
Careers
Value & Behaviors
Benefits
Open Positions
Contact
中
News
Press Releases
In The News
Media Room
Sep 25,2023
25
September 2023
AffaMed Therapeutics Announces Clinical Trial Application Approval in Mainland China for Risuteganib (Luminate
®
) First-in-Class Candidate for the Treatment of Intermediate Dry AMD
Sep 20,2023
20
September 2023
AffaMed Therapeutics Announces First Patient Treated in Phase 3 Registrational Clinical Trial in Mainland China for DEXTENZA
®
for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery
Aug 10,2023
10
August 2023
AffaMed Therapeutics Announces Partner Vistagen Reports Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder
Jun 14,2023
14
June 2023
AffaMed Therapeutics Announces Release of Headache Clinical Decision Support System
May 31,2023
31
May 2023
AffaMed Therapeutics Announces Completion of Patient Enrollment in the Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA
®
in Cataract Surgery Patients
<<
<
1
2
3
4
5
6
7
>
>>
下一页
